


**Product Name** : Zanubrutinib  
**Cat. No.** : PC-60535  
**CAS No.** : 1691249-45-2  
**Molecular Formula** : C<sub>27</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 471.561  
**Target** : BTK  
**Solubility** : 10 mM in DMSO



## Biological Activity

Zanubrutinib (BGB3111) is a potent, selective and orally available **Btk** inhibitor with IC<sub>50</sub> of 0.3 nM.

Zanubrutinib (BGB3111) shows much more restricted off-target activities against a panel of kinases, including ITK, compared with Ibrutinib.

Zanubrutinib (BGB3111) demonstrates nanomolar BTK inhibition activity, inhibits BCR aggregation-triggered BTK autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation in several MCL and DLBCL cell lines.

Zanubrutinib (BGB3111) demonstrates better anti-tumor activity than ibrutinib in TMD-8 subcutaneous xenograft model.

## References

Na Li, et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor. AACR.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com